{"transactions":[{"id":1662160,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":94688,"kind":"person","name":"Rebel Vivienne I","position":1,"cik":"0001947548","reported_name":"Rebel Vivienne I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Sci. & Med. Officer, EVP"}}],"security":"Common Stock","published_at":"2024-02-02T16:21:48.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":31847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024."}],"balance_after":46228,"source":{"system":"sec-edgar","filing":"0001493152-24-004762","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947548/000149315224004762/ownership.xml","form_type":"4"}},{"id":2107242,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":94688,"kind":"person","name":"Rebel Vivienne I","position":1,"cik":"0001947548","reported_name":"Rebel Vivienne I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Sci. & Med. Officer"}}],"security":"Common Stock, par value $0.007","published_at":"2022-11-22T16:49:39.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":7239,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant from bioAffinity Technologies, Inc. (the \"Issuer\") to Dr. Rebel of 7,239 restricted shares of the Issuer's common stock, par value $0.007 (the \"Common Stock\"), on November 17, 2022 under the Issuer's 2014 Equity Incentive Plan. The restricted stock will begin vesting on December 17, 2022 in 12 monthly installments, the first 11 of which will be of 603 shares of Common Stock and the last of which will be of the remaining 606 shares of Common Stock, subject to Dr. Rebel's continuous service to the Issuer through each vesting date."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant from bioAffinity Technologies, Inc. (the \"Issuer\") to Dr. Rebel of 7,239 restricted shares of the Issuer's common stock, par value $0.007 (the \"Common Stock\"), on November 17, 2022 under the Issuer's 2014 Equity Incentive Plan. The restricted stock will begin vesting on December 17, 2022 in 12 monthly installments, the first 11 of which will be of 603 shares of Common Stock and the last of which will be of the remaining 606 shares of Common Stock, subject to Dr. Rebel's continuous service to the Issuer through each vesting date."}],"balance_after":14381,"source":{"system":"sec-edgar","filing":"0001493152-22-033370","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947548/000149315222033370/ownership.xml","form_type":"4"}}]}